PMID- 19017837
OWN - NLM
STAT- MEDLINE
DCOM- 20081224
LR  - 20220331
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 84
IP  - 996
DP  - 2008 Oct
TI  - Recent advances in the management of type 2 diabetes mellitus: a review.
PG  - 524-31
LID - 10.1136/pgmj.2008.067918 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination 
      of insulin resistance and beta cell dysfunction. It is associated with an 
      increased and premature risk of cardiovascular disease as well as specific 
      microvascular complications such as retinopathy, nephropathy and neuropathy. In 
      the last 5 years new glucose lowering drugs acting on novel pathways have been 
      developed, licensed and launched, such as the glucagon-like peptide (GLP-1) 
      agonists (exenatide) and dipeptidyl peptidase (DPP-IV) inhibitors such as 
      sitagliptin and vildagliptin. This review looks at these new agents in terms of 
      their mode of action, pharmacokinetics and use in clinical practice. This review 
      also includes new agents in the area of weight loss that may have a positive 
      effect for glucose management-for example, rimonabant.
FAU - Srinivasan, B T
AU  - Srinivasan BT
AD  - Department of Diabetes Research, University Hospitals of Leicester NHS Trust, 
      Leicester, UK.
FAU - Jarvis, J
AU  - Jarvis J
FAU - Khunti, K
AU  - Khunti K
FAU - Davies, M J
AU  - Davies MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - RML78EN3XE (Rimonabant)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/antagonists & inhibitors
MH  - Piperidines/therapeutic use
MH  - Pyrazoles/therapeutic use
MH  - Rimonabant
RF  - 59
EDAT- 2008/11/20 09:00
MHDA- 2008/12/25 09:00
CRDT- 2008/11/20 09:00
PHST- 2008/11/20 09:00 [pubmed]
PHST- 2008/12/25 09:00 [medline]
PHST- 2008/11/20 09:00 [entrez]
AID - 84/996/524 [pii]
AID - 10.1136/pgmj.2008.067918 [doi]
PST - ppublish
SO  - Postgrad Med J. 2008 Oct;84(996):524-31. doi: 10.1136/pgmj.2008.067918.